1977PubMedRequires access

[Hemolytic disease of the newborn due to ABO incompatibility (author's transl)].

Konrad Fischer, A. Poschmann, Albert W. Grundmann

Open publisher page 5 citations

Abstract

Up to now, the exact diagnosis of ABO hemolytic disease of the newborn cannot be made either clinically or serologically. Affected babies are almost all either group A or group B from mothers of group O. In contrast to Rh hemolytic disease the immunological findings do not correlate well with the severity of the clinical course. Sometimes, it is impossible to differentiate between ABO hemolytic disease and non-antibody mediated hyperbilirubinemia. Pathogenetic aspects are discussed which may explain the differences between ABO and Rh hemolytic disease of the newborn. Aids to immunological and clinical diagnosis are given. Ante-natal treatment is not necessary. Indications for and technique of phototherapy and exchange transfusion are presented. Early application of these therapeutical methods prevents bilirubin encephalopathy, kernicterus with subsequent death or development of severe neurological sequelae.

About this research paper

What this paper is about

Up to now, the exact diagnosis of ABO hemolytic disease of the newborn cannot be made either clinically or serologically. Affected babies are almost all either group A or group B from mothers of group O. In contrast to Rh hemolytic disease the immunological findings do not correlate well with the severity of the clinical course. Sometimes, it is impossible to differentiate between ABO hemolytic disease and non-antibody mediated hyperbilirubinemia. Pathogenetic aspects are discussed which may explain the differences between ABO and Rh hemolytic disease of the newborn. Aids to immunological and clinical diagnosis are given. Ante-natal treatment is not necessary. Indications for and technique of phototherapy and exchange transfusion are presented. Early application of these therapeutical methods prevents bilirubin encephalopathy, kernicterus with subsequent death or development of severe neurological sequelae.

Why it matters

OpenAlex reports 5 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Up to now, the exact diagnosis of ABO hemolytic disease of the newborn cannot be made either clinically or serologically. Affected babies are almost all either group A or group B from mothers of group O. In contrast to Rh hemolytic disease the immunological findings do not correlate well with the severity of the clinical course. Sometimes, it is impossible to differentiate between ABO hemolytic disease and non-antibody mediated hyperbilirubinemia. Pathogenetic aspects are discussed which may explain the differences between ABO and Rh hemolytic disease of the newborn. Aids to immunological and clinical diagnosis are given. Ante-natal treatment is not necessary. Indications for and technique of phototherapy and exchange transfusion are presented. Early application of these therapeutical methods prevents bilirubin encephalopathy, kernicterus with subsequent death or development of severe neurological sequelae.

Key concepts: Kernicterus, ABO blood group system, Hemolytic disease of the newborn (ABO), Medicine, Disease, ABO incompatibility, Exchange transfusion, Haemolytic disease

Related papers

Back to paper searchBrowse research topicsOriginal source
[Hemolytic disease of the newborn due to ABO incompatibility (author's transl)]. — Research Paper | ScholarLens